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INTRODUCTION 
There is controversy among audiologists regarding the safety of the use of hearing aid 
programming equipment and assistive listening devices (HA/ALDs) in patients with implantable 
cardiac devices (Huch & Martin, 2014). ALDs are used in conjunction with hearing aids to allow 
those with hearing impairment to wirelessly access acoustic output from commonly used 
devices, such as a television, mobile phone, or microphone, with significantly reduced 
background noise. HA/ALDs are typically worn around the neck, in close proximity to the heart, 
as depicted in Figure 1. HA/ALD product materials list varying levels of warnings for the use of 
these devices concomitantly with cardiac devices (Huch & Martin, 2014; Phonak, 2014; Widex, 
2011). In the absence of published data, the safety of simultaneous use of HA/ALDs with cardiac 
devices remains unclear. This matter is especially urgent due to the growing number of cardiac 
device users who may also benefit from hearing aids. Nearly 66% of adults 70 years of age and 
older in the United States have hearing loss (Lin, Thorpe, Gordon-Salant, & Ferrucci, 2011) and 
approximately 70% of patients implanted with cardiac devices are 65 years of age or older 
(Zhan, Baine, Sedrakyan, & Steiner, 2008), indicating that a significant population of patients 
would benefit from both devices.  
Implanted cardiac devices include both pacemakers and automatic implantable cardiac 
defibrillators (AICDs).  Cardiac pacemakers are designed to sense normal cardiac activity, and in 
the absence of normal activity, deliver a pacing stimulus to maintain a normal heart rate. AICDs 
are designed to sense malignant arrhythmias and deliver a high-voltage shock to terminate the 
arrhythmias. In order to reliably detect both native cardiac activity and malignant arrhythmias, 
cardiac devices must detect signals as small as 0.3 mV with a frequency content up to several 
hundred Hz (ANSI/AAMI, 2007). Non-cardiac electrical signals, if misinterpreted by the device 
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as cardiac signals, can result in failure to deliver appropriate therapies, including failure to pace 
when needed, rapid pacing or asynchronous pacing, and failure to deliver a shock when needed, 
among other effects (ANSI/AAMI, 2007). In general, standards for devices which emit 
electromagnetic interference (EMI), including Federal Communications Commission (FCC) 
standards, are concerned with biological safety and not with potential interference from other 
devices. Standards are voluntary unless mandated by government regulations and are directed to 
device manufacturers, not healthcare providers or device users (ANSI/AAMI, 2007). 
Limited research has been published on the effects of HA/ALDs on cardiac devices. One 
study examined the effects of a hearing aid programming necklace on a pacemaker, as seen on 
the electrocardiogram (ECG) (Baranchuk, Kang, Shaw, & Witjes, 2008). This case study focused 
on interference that occurred as a result of the hearing aid programming necklace making contact 
with the ECG electrodes, an observation of limited utility as any type of contact with or 
manipulation of ECG electrodes may result in temporary artifact on the ECG. They did note that 
no permanent changes occurred in the programming of the single pacemaker being observed. 
The objective of this research is to provide information to audiologists and other 
professionals about the electronic operation parameters of cardiac devices and HA/ALDs. These 
devices are used daily by specialists in healthcare settings as well as by patients in various other 
environments. The potential for interference lies in the operation overlap of these devices. This 
overlap will be examined to determine the likelihood and consequences of interference, using a 
review of device standards, technical specifications, and empirical testing.  
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Magnetic field strength of HA/ALD	= 10 ∗ 1 ∗ 10 ∗	              
 
x: dBµA/m; r1: distance at which magnetic field density is desired; 
r2: distance at which field strength was measured as reported on data sheet 
Magnetic Field Strength of HA/ALD	=	
∗
	
 
4πr2: surface area of a sphere; c: speed of light; µ0: magnetic permeability of free space 
METHODS 
Technical Specifications Review 
Device technical specifications were reviewed to estimate magnetic field strength 
amplitude and potential frequency bandwidth overlap between HA/ALDs and cardiac devices, as 
summarized in Table 1. Specifications for the Widex M-DEX, TV-DEX, USBlink, and the 
Phonak iCube II, and ComPilot documented a measured magnetic field strength (in dBµA/m) at 
a distance of 10 meters, a standard distance for this measurement. These values were converted 
to A/m in order to compare to cardiac device standards and scaled to determine field strength at a 
distance of 5 cm. This allowed the investigators to estimate HA/ALD output at a distance similar 
to actual use (i.e., in close proximity to the chest). The following equation, derived in Appendix 
B, was used for these calculations: 
 
 
 
The Phonak Inspiro, Roger Pen, and RemoteMic technical specifications did not list a 
measured field strength. Instead, radio frequency power was listed. This measure was assumed to 
be equal to Effective Radiated Power (ERP) for the purposes of this study and is the power 
emitted by the device. ERP was used to calculated power density at a distance of 5 cm, which 
was then used to calculate magnetic field strength in A/m in order to compare with the other 
HA/ALDs in this study. The following equation, derived in Appendix A, was used: 
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Empirical Testing 
Empirical testing was performed using the following explanted Medtronic cardiac 
devices: Consulta CRT-D (pacemaker defibrillator), Adapta L (pacemaker), and Advisa DR 
(MRI-compatible pacemaker).These devices had been explanted for reasons not related to device 
malfunction. Cardiac devices and their programming equipment were acquired from Medtronic, 
Inc. and the Cardiovascular Division at Barnes-Jewish Hospital. HA/ALDs were borrowed from 
the Adult Audiology Division at the Center for Advanced Medicine. All devices exhibited 
normal function. 
Testing was conducted in the clinical electrophysiology laboratory at Barnes-Jewish 
Hospital. To generate a cardiac signal for device detection, the devices and lead were taped to the 
chest of a volunteer and conductive gel used to ensure good electrical contact; the device sensed 
native cardiac activity in this configuration.  To increase the likelihood of interference, a unipolar 
lead configuration was used and device sensitivity thresholds were decreased to 0.3 mV on each 
cardiac device.  Communication with the cardiac devices was established using the manufacturer 
specific programmer (Medtronic) and the device response to EMI was continuously monitored. 
HA/ALDs were arranged in two ways: hearing aids were worn on the ears bilaterally with ALDs 
and programming necklaces positioned at a distance similar to typical usage (i.e., around the 
neck, clipped to the volunteer’s shirt) or directly on top of the cardiac device. Configurations are 
depicted in Figure 1.  
HA/ALD activity was generated through standard usage and programming. To test for 
potential interference during hearing aid programming, the Widex USBlink programmer was 
positioned around the volunteer’s neck. The Widex Dream 9 BTE hearing aids were placed on 
the volunteer’s ears and connected to the NOAH programming software wirelessly via the 
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USBlink. Intensity was increased/decreased, programs were added/removed, and a feedback test 
was attempted via the programming software. It should be noted that a complete feedback test 
was not performed due to excessive noise in the environment. This procedure was repeated in an 
identical manner using the Phonak iCube II Programmer and Bolero Q90P BTE hearing aids.  
Tests were conducted with ALDs both in the typical position as well as deliberately positioned 
atop the cardiac device to maximize potential interference. 
To test for EMI from hearing aid-specific ALDs during standard usage, cardiac devices, 
hearing aids, and ALDs were worn by a volunteer. Audio was streamed via Bluetooth® (2.4 
GHz) from a cell phone (Motorola Moto X) to the ComPilot and TV-DEX, which were 
connected to the appropriate hearing aids via a 10.6 MHz wireless connection. The RemoteMic, 
Inspiro, and M-DEX were tested in a similar manner. The investigators stood at a distance and 
spoke into the microphones of the aforementioned ALDs which were wirelessly connected to 
their hearing aid counterparts. Volume was manipulated by the volunteer. 
 Manufacturer-specific (Medtronic) cardiac device programmers were used to monitor 
cardiac activity, detect HA/ALD activity, and detect any resultant cardiac device programming 
or behavioral changes. These changes include inhibition of pacing or inappropriate anti-
tachycardia therapy. The Medtronic Consulta CRT-D and Adapta L were connected to the 
programmer wirelessly. The Medtronic Advisa DR was connected via a programming magnet 
placed over the device. It should be noted that worst case scenario configuration was slightly 
altered during Advisa DR testing to avoid the programming wand (i.e., hearing aids were 
positioned on the chest, slightly farther away from the cardiac device). Cardiac device activity 
was observed via electrogram tracings that were printed from cardiac device programmers in real 
time.  
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RESULTS 
Technical Specification Review 
 Cardiac devices are engineered to avoid interference by non-cardiac signals and devices 
are tested extensively in accordance with published standards (ANSI/AAMI, 2007).  Devices 
which meet these standards are expected to be largely resistant to electromagnetic interference 
outside of the frequency range required for normal sensing and operation.  These standards are 
summarized in Figure 3, which illustrates the ranges of frequency and field strength which are 
predicted to have little or no impact on device function (zone 2 in Figure 3).  To determine 
whether EMI emitted by ALDs is likely to affect cardiac device performance, we reviewed the 
published technical specifications for assistive listening devices and calculated the predicted 
field strength and frequency (as described above).  Estimated magnetic field strengths at a 
distance of 5 cm are summarized in Table 1 and plotted on Figure 3. The majority of HA/ALDs 
field strength amplitudes are well below the threshold for anticipated device interaction. All 
HA/ALDs, including those with field strength amplitudes above the threshold for interference, 
operate at a higher frequency than those predicted to affect cardiac devices. Notably, the 
strongest HA/ALD output is ten times weaker than that of a cell phone at the same distance 
(FCC, n.d.).   
Empirical Testing 
To further evidence the lack of interaction between ALDs and cardiac devices, 
representative devices manufactured by Medtronic, Inc. were tested as described in Methods.  
During empiric testing of a representative cardiac pacemaker, defibrillator, and MRI-compatible 
defibrillator, no HA/ALD activity was detected by the cardiac devices regardless of device 
configuration or manipulation.  Figure 2 shows a representative tracing of the sensed cardiac 
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signal during ALD usage; EMI from the ALD usage remained undetectable.  No changes in 
device activity, including pacing or arrhythmia detection occurred during exposure to EMI from 
ALD usage.  
The Medtronic Adapta L (pacemaker) was not tested with Phonak products (see Table 1) 
due to an inexplicable change in electrogram morphology during ComPilot testing. The 
ComPilot was turned off and the pacemaker ports were cleaned. Abnormal electrogram 
morphology remained despite cessation of testing. Further investigation with this pacemaker was 
discontinued as the source of interference could not be determined. 
DISCUSSION 
As medical device usage becomes more widespread, consideration must be given to 
potential interactions between devices.  Regulatory statues for devices which emit 
electromagnetic energy are confined to avoiding direct biological effects and do not encompass 
impact on other devices (ANSI/AAMI, 2007). This study examined the potential interaction 
between two of the most commonly used devices: implanted cardiac devices (pacemakers and 
defibrillators) and assistive listening devices.   
To an even greater degree than ALDs, cell phones are ubiquitous devices for which EMI 
with cardiac devices has also been debated for some time. Burri et al (2016) examined the effects 
of modern 4G cell phones on patients with AICDs. Cardiac devices were tested with therapies 
deactivated to ensure patient safety (i.e., AICDs would not deliver a shock if EMI was 
misinterpreted as an arrhythmia). Testing was completed in low cellular network areas to 
increase the likelihood of interference, as emissions are increased when cell phones are searching 
for a better signal. They reported that no interference was observed on electrogram tracings 
during testing. They also noted that current cell phone technology and improvements in cardiac 
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device shielding allow for almost negligible EMI. These findings support the current study and 
the same assumption of low EMI risk can be extended to HA/ALDs. 
Although cardiac devices are heavily engineered for resistance to inference by 
environmental EMI, EMI interactions are extremely complex. Potential for interaction depends 
on the frequency content of emitter, modulation format, power of signal, proximity to patient, 
coupling factors, and duration of exposure making it nearly impossible to exclude every potential 
scenario in which interaction can occur (ANSI/AAMI, 2007).  However, based on device 
engineering, the general ranges of frequency and electromagentic field strength against which 
cardiac devices are expected to be resistant can be estimated.  As shown here, published details 
of the frequency and emitted field of HA/ALDs indicate that HA/ALD-emitted EMI is extremely 
unlikely to impact cardiac device function.  This conclusion is further strengthened by limited 
empiric testing which demonstrated a failure of representative cardiac devices to even detect, 
much less be affected by, the HA/ALD-emitted EMI. 
LIMITATIONS 
The wide variety of both cardiac devices and HA/ALDs, in addition to the complexity of 
electromagnetic field propagation and interaction, makes it essentially impossible to exclude any 
possible interaction.  In addition, simplifying assumptions regarding the electromagnetic field 
emitted by HA/ALDs was required to estimate field strengths and allow direct comparisons 
between devices.   
CONCLUSION 
Due to the complexity of EMI, variations in individual anatomy, the large number of 
different implantable cardiac devices, and the large number of different HA/ALDs, it is 
impossible to definitively rule out the possibility of EMI. However, HA/ALDs operate with a 
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power output and in a frequency range which is extremely unlikely to cause significant 
interference with cardiac devices. Empiric ex vivo testing of select devices confirmed that the 
cardiac devices failed to sense HA/ALD-generated signals. Although specific cases of potential 
interaction require assessment by a cardiologist or manufacturer representative, HA/ALDs can 
most likely be used by patients with implanted cardiac devices without concern.  
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Table 1. Summary of device technical specifications. *Devices not empirically tested - listed for comparison only. 
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Legend 
Cardiac Device 
Hearing Aids 
Programming Necklace or ALD 
Wireless transmission of 
acoustic signal              
Computer or Audio Source 
a) b) 
Figure 1. Depiction of device orientation a) during typical use and b) to maximize interference. 
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Figure 2. Cardiac device activity – no difference in tracings at baseline and during device use. 
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Figure 3. Estimated frequency and field strength resulting in EMI affecting implanted 
cardiac devices. Adapted from Figure M.4 – Magnetic Fields and used with permission 
from ANSI/AAMI 2012 
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APPENDIX A 
 
Derivation of Magnetic Field Strength Calculation (given ERP) (Inan & Inan, 1999):  
 
Equation 1: 
 
 
 
 
 
 
 
 
Equation 2: 
 
 
 
 
 
 
 
 
 
Equation 1 and 2 combine to give Equation 3: 
 
 
 
 
 
 
 
 
Equation 4: 
 
 
 
 
 
 
 
Equation 3 and 4 combine to give Equation 5: 
 
  
4
 
 
S: power density;  
r: distance from the source (HA/ALD) 
∗ 0  
 
B: magnetic flux density;  
: magnetic permeability of free space; c: speed of light 
4
0
1 ∗
0
4
	
0
  
 
H: magnetic field intensity 
1
∗
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APPENDIX B 
 
Derivation of Magnetic Field Strength Calculation (at one distance, given magnetic field 
intensity at another distance): 
(Inan and Inan, 1999) 
 
Equation 6: Given magnetic field strength (H1) at a given distance (r1) and rearranging Equation 
5 (in Appendix I): 
 
 
 
 
 
 
 
 
 
 
To find a magnetic field intensity (H2) at a given distance (r2) using the same value of ERP, 
Equation 6 into Equation 5 gives: 
 
 
 
 
 
 
 
Convert dBµA/m to A/m: 
 
 
∗ 4
 
 
H1: magnetic field intensity; r1: distance 
 
10 ∗ 1 ∗ 10  
 
y: A/m; x: dBµA/m 
